Showing results (251-260 of 400) with videos related to

Sort By:
Pageof 40
Minerva Cardioangiologica|July 15, 2009
Fingerprints and cardiovascular risk. The San Valentino fingerprint vascular screening project (SanVal/FP)G Belcaro, M R Cesarone, A Ledda, et al.
Thrombosis Research|February 1, 1993
Studies on the pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV2-Lys 47) after intravenous and subcutaneous administration in dogsL Iyer, M Koza, O Iqbal, et al.
Thrombosis Research|November 1, 1996
Defibrotide mediated inhibition of serotonin, endothelin-I, thromboxane, and serum induced contraction of canine femoral and pulmonary arterial ringsL H Yang, D A Hoppensteadt, O Iqbal, et al.
Thrombosis Research|March 14, 2000
A synthetic inhibitor of factor Xa, DX-9065a, reduces proliferation of vascular smooth muscle cells in vivo in ratsB Kaiser, M Paintz, O Scholz, et al.
International Angiology : a Journal of the International Union of Angiology|March 1, 1996
Physical and pharmacologic manipulation of the vascular system as measured by the release of TFPI and other mediators of antithrombotic actionsD A Hoppensteadt, W Jeske, J Fareed, et al.
The American Journal of Cardiology|September 16, 1998
Rationale for the management of coronary syndromes with low-molecular-weight heparinsE Gurfinkel, J Fareed, E Antman, et al.
Thrombosis Research|March 1, 1994
Comparative studies on the inhibitory spectrum of recombinant hirudin, DuP 714 and heparin on thrombin and factor Xa generation in biochemically defined systemsB Kaiser, D Callas, D Hoppensteadt, et al.
Seminars in Thrombosis and Hemostasis|November 5, 1999
Pharmacokinetics of low molecular weight heparins in animal modelsJ Fareed, K Fu, L H Yang, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1995
Development and validation of two enzyme-linked immunosorbent assay (ELISA) methods for recombinant hirudinL Iyer, M Adam, J Amiral, et al.
Thrombosis Research|March 1, 1996
Modulation of platelet function and vascular smooth muscle contractile actions by a novel, selective, highly potent 5-HT2 antagonist (SR46349)L H Yang, D Callas, J M Herbert, et al.
Pageof 40